Texas-based biotechnology company, Repros Therapeutics Inc, known for the development of small molecule drugs to manage issues of the female genital tract, has announced its collaboration with the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center and Feinberg School of Medicine.
http://bionews-tx.com/news/2013/04/30/repros-therapeutics-proellex-enters-breast-cancer-phase-2-study-in-collaboration-with-northwestern-university/
No comments:
Post a Comment